The global demand for Novel Drug Delivery Systems in Cancer Therapy Market is presumed to reach the market size of nearly USD 54.98 MN by 2028 from USD 12.26 MN in 2021 with a CAGR of 23.7% under the study period 2022 - 2028.
Novel drug delivery systems in cancer therapy aim to deliver medication in a manner that increases its concentration at a specific site relative to other parts of the body. A novel drug delivery system (NDDS) offers better patient compliance via the diminished frequency of dose. NDDS have significant advantages for cancer treatment, including improved solubility and bioavailability, reduced toxicity, maximum therapeutic effect, sustained and controlled drug delivery, increased stability and better security against physical and biochemical degradation.
The global novel drug delivery systems in the cancer therapy market are likely to expand due to substantial benefits for cancer treatment. Also, the novel drug delivery systems market is mainly influenced by a rise in the incidences of cancer. Moreover, rise in research activities for the development of technologies of novel drug delivery coupled with augmented funding for ongoing research projects. Furthermore, a rise in healthcare expenditure for the diagnosis and treatment of cancer is likely to propel the NDDS market growth. However, the high cost of therapy may limit the market growth.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of novel drug delivery systems in cancer therapy. The growth and trends of novel drug delivery systems in cancer therapy industry provide a holistic approach to this study.
This section of the novel drug delivery systems in cancer therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
- Nanoparticles (Liposomes, Polymers, Micelles, Other Nanoparticles)
- Embolization Particles (Pva Particles, Drug-Eluting Beads, Liquid Emboli, Other Embolization Particles)
This section covers the regional outlook, which accentuates current and future demand for the Novel Drug Delivery Systems in Cancer Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Novel Drug Delivery Systems in Cancer Therapy Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the novel drug delivery systems in cancer therapy market include Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., GALEN, Merrimack Pharmaceuticals Inc., Shire, Samyang Biopharmaceuticals Corporation, Celgene Corporation, Spectrum Pharmaceuticals Inc., BTG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.